Amanda Liddy

Amanda Liddy

Auto-generated profile, based on publicly available information

Amanda Liddy

Mediprobe Research Inc. London Ontario Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Aditya K GuptaAditya K Gupta
Aditya K Gupta
SUSusmita
Susmita
HNHien C. Nguyen
Hien C. Nguyen
ALAmanda Liddy
Amanda Liddy
VEVasiliki Economopoulos
Vasiliki Economopoulos
TWTong Wang
Tong Wang
Background/Objectives: Terbinafine has been the gold standard for the management of superficial fungal infections. The etiological agent generally is Trichophyton rubrum (T. rubrum); however, there has been increased reporting of a new terbinafine-resistant strain of the T. mentagrophytes complex (T. mentagrophytes ITS genotype VIII otherwise known as T. indotineae). Here, we review the epidemiology, clinical features, diagnosis, and treatment of T. rubrum and T. indotineae infections. Methods: We conducted a systematic literature search using PubMed, Embase (Ovid), and Web of Science, resulting in 83 qualified studies with data summarized for clinical features, antifungal susceptibility, and terbinafine resistance mechanisms and mutations. Results: Dermatophytosis is most commonly caused by T. rubrum; however, in certain parts of the world, especially in the Indian subcontinent, T. indotineae infections have been reported more frequently. The majority of T. rubrum isolates remain susceptible to terbinafine (over 60% of isolates show MIC50 and MIC90 < 0.5 µg/mL). In contrast, for T. indotineae, 30% of isolates exhibit MIC50 ≥ 0.5 µg/mL and 80% exhibit MIC90 ≥ 0.5 µg/mL. Frequently detected squalene epoxidase (SQLE) mutations in T. rubrum are Phe397Leu/Ile (41.6%) and Leu393Phe (20.8%); in T. indotineae, these include Phe397Leu (33.0%) and Ala448Thr (24.5%). Other potential terbinafine resistance mechanisms in T. rubrum and T. indotineae are discussed. Conclusions: T. rubrum generally remain susceptible in vitro to terbinafine in contrast to T. indotineae. The essential components of an effective antifungal stewardship emphasize accurate clinical and laboratory diagnosis, susceptibility testing, and appropriate antifungal therapy selection with a multidisciplinary approach.

4 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
Aditya K GuptaAditya K Gupta
Aditya K Gupta
HNHien C. Nguyen
Hien C. Nguyen
ALAmanda Liddy
Amanda Liddy
MTMesbah Talukder
Mesbah Talukder
TWTong Wang
Tong Wang
VPVincent Piguet
Vincent Piguet
There has been a recent shift in the epidemiology of superficial fungal infections (tinea, dermatophytosis, dermatomycoses). Trichophyton indotineae is an emerging dermatophyte species of significant global concern for its contagious nature and antifungal drug resistance. This scoping review includes available clinical and laboratory assessments of T. indotineae to provide a comprehensive up‐to‐date overview of its epidemiology, clinical manifestations, diagnostic approaches, antifungal susceptibility patterns, resistance mechanisms and management strategies. We discuss T. indotineae resistance against standard and newer antifungals (terbinafine, griseofulvin and triazoles including fluconazole, itraconazole, voriconazole and posaconazole). In particular, the terbinafine susceptibility profile of T. indotineae can be linked to squalene epoxidase ( SQLE ) single‐nucleotide variations. For diagnosis, it is not possible to separate T. indotinea e from other members of the T. mentagrophytes complex ( T. mentagrophytes and T. interdigitale ) without access to molecular diagnostic methods. So, in patients presenting with extensive dermatophytoses, with a history of treatment resistance and/or recent travel, molecular diagnosis to confirm T. indotineae infection should be considered. Healthcare providers often face challenges in choosing between terbinafine and itraconazole treatments. While the use of terbinafine is limited due to resistance, itraconazole is hindered by erratic absorption, possible drug interactions and side effects as well as resistance in some cases. Newer treatments being investigated include super‐bioavailable itraconazole, third‐generation triazoles (voriconazole, posaconazole) and topical‐oral combination regimens. The need for improved diagnostic accessibility, judicious antifungal prescribing, and implementing an effective antifungal stewardship program are highlighted.

13 August 2025 in Life
Verified
Journal Article
Open access
PDF file
Aditya K GuptaAditya K Gupta
Aditya K Gupta
ALAmanda Liddy
Amanda Liddy
LMLee Magal
Lee Magal
Avner ShemerAvner Shemer
Avner Shemer
ECElizabeth Cooper
Elizabeth Cooper
TWTong Wang
Tong Wang
Onychomycosis is a prevalent and clinically relevant complication among individuals with diabetes. It is associated with an elevated risk of secondary fungal and bacterial infections, foot ulceration, and, in advanced cases, amputation. Factors contributing to the increased prevalence of onychomycosis in this population include age, peripheral vascular disease, poor glycemic control, neuropathy, suboptimal foot hygiene, and nail trauma. While dermatophytes are the most common pathogens, diabetic patients are more prone to mixed infections involving Candida species with varying antifungal susceptibility profiles, necessitating accurate identification to guide therapy. Prompt diagnosis and early intervention are important to prevent complications. Systemic antifungals such as terbinafine and itraconazole are considered first-line therapies, particularly for moderate to severe onychomycosis. However, drug interactions, renal, hepatic, and metabolic comorbidities may necessitate individualized treatment plans. For patients with mild to moderate disease, or contraindications to oral therapy, topical agents such as efinaconazole or tavaborole offer viable alternatives. Adjunctive measures, including education on foot hygiene, prompt treatment of tinea pedis, and environmental sanitization, are important in preventing recurrence and reinfection. This review summarizes the epidemiology, diagnosis, and treatment considerations for onychomycosis in diabetic patients, emphasizing the need for individualized care to improve outcomes in this high-risk population.

11 July 2025 in Mycoses
Verified
Journal Article
Open access
Aditya K GuptaAditya K Gupta
Aditya K Gupta
ALAmanda Liddy
Amanda Liddy
LMLee Megal
Lee Megal
BKBaruch Kaplan
Baruch Kaplan
ASAvner Shemer
Avner Shemer
TWTong Wang
Tong Wang
Sexually transmitted dermatophyte infections are an emerging public health concern, with increasing incidence reported across multiple countries. These infections are mainly spread through direct skin‐to‐skin contact during sexual activity and are more commonly found in individuals with high‐risk sexual practices. The likelihood of infection is heightened by frequent pubic hair grooming or regular use of shared spaces like gyms and saunas. Clinically, presentations are often severe, widespread and atypical, which may delay diagnosis or lead to misidentification. Accurate species‐level identification is critical and increasingly reliant on molecular sequencing techniques, including ITS and tef1α regions, which are also valuable for strain surveillance and contact tracing. Management strategies should emphasise systemic antifungal therapy, with consideration for adjunctive topical agents or antibiotics in cases of secondary infection. Individualised treatment plans may require extended therapy durations or combination regimens to ensure clinical resolution. In addition to pharmacologic intervention, education on hygiene practices, risk of reinfection and the importance of environmental decontamination and follow‐up care is essential for preventing recurrence and curbing transmission.

1 March 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
Aditya K GuptaAditya K Gupta
Aditya K Gupta
ALAmanda Liddy
Amanda Liddy
TWTong Wang
Tong Wang
BKBaruch Kaplan
Baruch Kaplan
ASAvner Shemer
Avner Shemer
MTMesbah Talukder
Mesbah Talukder
Over the past decade, reports of difficult-to-treat, antifungal-resistant superficial fungal infections have increased markedly, raising global concern among clinicians and public health authorities. Trichophyton mentagrophytes ITS genotype VIII, more recently classified as T. indotineae, has emerged as a principal driver of this shift, with infections often presenting as inflammatory, extensive dermatophytoses that are prone to persistence and relapse despite antifungal therapy. This scoping review synthesizes literature published between 2019 and 2025 to provide a comprehensive overview of emerging trends in epidemiology, clinical features, antifungal susceptibility, molecular resistance mechanisms, and management strategies. Resistance in T. indotineae contributes not only to prolonged disease courses and recurrent infections but also to intrafamilial and community outbreaks, highlighting the species’ capacity for rapid and widespread transmission. These challenges are compounded by diagnostic limitations, variable correlation between squalene epoxidase gene mutations and terbinafine susceptibility, and the continued reliance on terbinafine as a first-line systemic therapy in many regions. Together, these factors underscore the urgent need for integrated diagnostic and management approaches, combining phenotypic susceptibility testing, genotypic analysis, and careful clinical assessment. Moreover, updated treatment guidelines and coordinated public health interventions are critical to mitigate transmission, optimize therapeutic outcomes, and address the growing clinical and epidemiological burden posed by resistant T. indotineae infections worldwide.

30 October 2025 in International Journal of Dermatology
Verified
Journal Article
Open access
Aditya K GuptaAditya K Gupta
Aditya K Gupta
ALAmanda Liddy
Amanda Liddy
VEVasiliki Economopoulos
Vasiliki Economopoulos
RMRenata Magalhaes
Renata Magalhaes
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder increasingly recognized as a systemic disease with diverse comorbidities. While several comorbid conditions are well documented, regional differences in prevalence remain unclear. Objective: The aim of this study was to evaluate regional variation in major comorbidities among HS patients, including diabetes, hypertension, depression, smoking, thyroid disorders, acne, obesity, psoriasis, and inflammatory bowel disease. Methods: We performed a meta‐analysis of proportions using a generalized linear mixed model with a binomial distribution and logit link to compare the prevalence of HS‐associated comorbidities across North America, Europe, and the Middle East/Asia. Analyses were stratified by adult and pediatric populations, with regional N‐values incorporated. Results: Significant regional differences were observed in metabolic, endocrine, and psychiatric comorbidities. North American patients had higher odds of diabetes compared to Europe (odds ratio [OR] 1.92) and hypertension compared to the Middle East/Asia (OR 2.99). Depression and thyroid disorders were more common in North America (OR 3.46 and 2.32) and Europe (OR 3.19 and 4.01) compared to the Middle East/Asia. Smoking was more prevalent in Europe compared to North America (OR 0.28) and the Middle East/Asia (OR 2.26). Among pediatric patients, anxiety (OR 0.05) and depression (OR 0.16) were more common in North America, while smoking was more frequent outside North America (OR 12.67). Conclusions: Regional variation in comorbidity prevalence likely reflects differences in lifestyle, diet, sociocultural norms, healthcare literacy, and access to care. Recognizing these patterns may support earlier identification, guide preventive efforts, and inform individualized management strategies in HS.